On the 1st of June 2016, Medical Prognosis Institute A/S ("MPI") will present at Sedermeradagen in Gothenburg. The Chief Investor Relations & Communications Officer of MPI, Ulla Hald Buhl, will present the company between 13:50 - 14:20.
Sedermeradagen in Gothenburg 2016 takes place at Clarion Hotel Post, and starts with a breakfast mingle at 07:45. This is followed by a day with company presentations and questionings. Sedermeradagen is an investor day arranged by Sedermera Fondkommission, as an opportunity for investors to meet interesting companies within the micro and smallcap segment in Sweden.
Sedermeradagen is also broadcasted live at www.sedermeradagen.se
For more information and registration:
Telephone: 0431 - 47 17 00
For additional information about MPI:
| Peter Buhl Jensen, VD |
Telephone: +45 21 60 89 22
| Ulla Hald Buhl, Chief Investor Relations and Communications |
Telephone: +45 21 70 10 49
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Danmark
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereasthe messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.